CLAIMS

1. A method of treating a subject having cancer, the method comprising administering to the subject a therapeutically effective amount of VS-6063, or a pharmaceutically acceptable salt thereof, in combination with CH5126766, or a pharmaceutically acceptable salt thereof, thereby treating the subject, wherein the cancer is a cancer with a RAS mutation.

2. The method of claim 1, wherein the CH5126766 or pharmaceutically acceptable salt thereof is a potassium salt of CH5126766.

3. The method of claim 1 or 2, wherein the cancer is selected from the group consisting of ovarian cancer, lung cancer, colon cancer, and pancreatic cancer.

4. The method of any one of claims 1-3, wherein the cancer is ovarian cancer.

5. The method of claim 4, wherein the ovarian cancer is low grade serous ovarian cancer.

6. The method of any one of claims 1-3, wherein the cancer is lung cancer.

7. The method of any one of claims 1-3, wherein the cancer is colon cancer.

8. The method of any one of claims 1-3, wherein the cancer is pancreatic cancer.

9. The method of any one of claims 1-8, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed twice a week.

10. The method of any one of claims 1-9, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed twice daily.

11. The method of any one of claims 1-9, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed once daily.

12. The method of any one of claims 1-11, wherein the CH5126766 or pharmaceutically acceptable salt thereof and the VS-6063 or pharmaceutically acceptable salt thereof are dosed for at least three weeks.

13. The method of any one of claims 1-12, wherein the CH5126766 or pharmaceutically acceptable salt thereof and the VS-6063 or pharmaceutically acceptable salt thereof are independently dosed cyclically for three weeks on and then one week off.

14. The method of any one of claims 1-12, wherein the CH5126766 or pharmaceutically acceptable salt thereof and the VS-6063 or pharmaceutically acceptable salt thereof are simultaneously dosed cyclically for three weeks on and then one week off.

15. The method of any one of claims 1-14, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 0.5 mg to about 10 mg.

16. The method of any one of claims 1-14, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 4 mg.

17. The method of any one of claims 1-14, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at 3.2 mg.

18. The method of any one of claims 1-17, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 100 mg to about 400 mg.

19. The method of any one of claims 1-17, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 100 mg to about 500 mg.

20. The method of any one of claims 1-17, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 200 mg to about 500 mg.

21. The method of any one of claims 1-17, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 200 mg to about 600 mg.

22. The method of any one of claims 1-14, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 0.5 mg to about 10 mg and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 100 mg to about 400 mg.

23. The method of any one of claims 1-14, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 4 mg twice a week and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 200 mg twice daily.

24. The method of any one of claims 1-14, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at 3.2 mg twice a week and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at 200 mg twice daily.

25. The method of any one of claims 1-14, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 4 mg twice a week and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 400 mg twice daily.

26. The method of any one of claims 1-14, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at 3.2 mg twice a week and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at 400 mg twice daily.

27. A method of treating a subject having cancer, the method comprising administering to the subject a therapeutically effective amount of CH5126766, or a pharmaceutically acceptable salt thereof, in combination with VS-6063, or a pharmaceutically acceptable salt thereof.

28. The method of claim 27, wherein the cancer is selected from the group consisting of ovarian cancer, lung cancer, colon cancer, and pancreatic cancer.

29. The method of claim 27 or 28, wherein the cancer is ovarian cancer.

30. The method of claim 29, wherein the ovarian cancer is low grade serous ovarian cancer.

31. The method of claim 27 or 28, wherein the cancer is lung cancer.

32. The method of claim 27 or 28, wherein the cancer is colon cancer.

33. The method of claim 27 or 28, wherein the cancer is pancreatic cancer.

34. The method of any one of claims 27-33, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed twice a week.

35. The method of any one of claims 27-34, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed twice daily.

36. The method of any one of claims 27-34, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed once daily.

37. The method of any one of claims 27-36, wherein the CH5126766 or pharmaceutically acceptable salt thereof and the VS-6063 or pharmaceutically acceptable salt thereof are dosed for at least three weeks.

38. The method of any one of claims 27-37, wherein the CH5126766 or pharmaceutically acceptable salt thereof and the VS-6063 or pharmaceutically acceptable salt thereof are independently dosed cyclically for three weeks on and then one week off.

39. The method of any one of claims 27-37, wherein the CH5126766 or pharmaceutically acceptable salt thereof and the VS-6063 or pharmaceutically acceptable salt thereof are simultaneously dosed cyclically for three weeks on and then one week off.

40. The method of any one of claims 27-39, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 0.5 mg to about 10 mg.

41. The method of any one of claims 27-39, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 4 mg.

42. The method of any one of claims 27-39, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at 3.2 mg.

43. The method of any one of claims 27-42, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 100 mg to about 400 mg.

44. The method of any one of claims 27-42, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 100 mg to about 500 mg.

45. The method of any one of claims 27-42, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 200 mg to about 500 mg.

46. The method of any one of claims 27-42, wherein the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 200 mg to about 600 mg.

47. The method of any one of claims 27-39, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 0.5 mg to about 10 mg and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 100 mg to about 400 mg.

48. The method of any one of claims 27-39, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 4 mg twice a week and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 200 mg twice daily.

49. The method of any one of claims 27-39, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at 3.2 mg twice a week and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at 200 mg twice daily.

50. The method of any one of claims 27-39, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at about 4.0 mg twice a week and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at about 400 mg twice daily.

51. The method of any one of claims 27-39, wherein the CH5126766 or pharmaceutically acceptable salt thereof is dosed at 3.2 mg twice a week and the VS-6063 or pharmaceutically acceptable salt thereof is dosed at 400 mg twice daily.

52. The method of any one of claims 27-51, wherein the cancer is caused by a mutation in RAS or BRAF.

53. The method of any one of claims 27-51, wherein the cancer is caused by a KRAS mutation or NRAS mutation.